EXL (EXLS) Q4 2025 earnings review
Strong 2025 Finish, But AI Narrative Meets Decelerating 2026 Guidance
EXL delivered a solid finish to 2025, with Q4 revenue up 12.7% YoY and adjusted EPS jumping 15.0%. The pivot to a Data & AI-led strategy continues to yield results, particularly in Healthcare & Life Sciences, which surged 26.2% YoY. However, cracks are appearing in the growth story: 2026 guidance projects 9-11% revenue growth, a clear deceleration from the 13.6% achieved in 2025 and 12.7% in 2024. Despite management's narrative that AI efficiency gains lead to expanding wallet share, top-line momentum is cooling, and the Insurance segment is actively lagging. A newly authorized $500M buyback program provides a floor, but investors must weigh the AI hype against stabilizing margins and slowing headline growth.
🐂 Bull Case
EXL's structural shift to embed AI into mission-critical workflows is successfully moving the company away from commoditized BPO work, securing sticky revenue and supporting an expansion in gross margins (38.6% in 25Q4 vs 38.1% in 24Q4).
Healthcare & Life Sciences revenue accelerated significantly, growing 26.2% YoY in Q4 to $142.2M, acting as a massive growth engine and validating the company's domain-specific LLM investments.
🐻 Bear Case
Management has long touted EXL as a reliable mid-teens grower. The 2026 revenue guidance of 9-11% breaks this trend, signaling that macroeconomic uncertainty or AI deflationary pressures might be taking a toll.
The Insurance unit—EXL's largest segment—grew just 7.2% YoY in Q4, significantly underperforming the company average and dragging down overall top-line performance.
⚖️ Verdict: ⚪
Neutral. The business quality is exceptional, cash generation is strong, and the AI pivot is legitimate. However, paying a premium multiple requires accelerating or sustained mid-teens growth; the 2026 deceleration guidance makes this a 'show me' story for the next few quarters.
Key Themes
Agentic AI as a Differentiator (EXLdata.ai)
The newly unveiled EXLdata.ai suite highlights a shift from basic GenAI to 'Agentic AI'. By deploying AI agents that autonomously manage data governance, lineage, and modernization, EXL is solving the biggest bottleneck for clients: making legacy unstructured data 'AI-ready'. This specific technological capability allows them to win complex deals that standard BPO competitors cannot touch.
Healthcare Segment Leading the Charge
Healthcare & Life Sciences is officially the company's powerhouse. Accelerating from ~22% growth in mid-2025 to 26.2% in Q4, it now represents 26% of total revenue. This is driven by deep domain expertise, payment integrity solutions, and the rollout of payer-focused LLMs for medical data extraction.
Defeating the AI Cannibalization Threat
A persistent market concern is that AI-driven productivity gains (doing 100 hours of work in 10 hours) will cannibalize BPO billable hours. EXL is actively countering this by using efficiency to capture larger wallet share from clients. They are transitioning from FTE-based pricing to outcome-based pricing, keeping revenue flat-to-up while improving stickiness.
Guidance Contradicts 'Unstoppable Momentum' Narrative
Management's narrative has consistently positioned AI as an accelerant. Yet, 2026 revenue guidance (9-11%) and adjusted EPS guidance (10-12%) represent a noticeable deceleration from 2025 actuals (13.6% and 18.0%, respectively). If AI is opening vast new TAMs and driving workflow takeovers, headline growth should be accelerating, not stepping down into the single digits.
Insurance Segment Drag
Insurance remains EXL's largest reporting segment but is firmly a laggard. Q4 YoY growth was just 7.2% ($185.8M), down from the 8-9% range seen earlier in the year. If EXL cannot re-accelerate its core vertical, achieving the higher end of 2026 guidance will rely entirely on Healthcare sustaining its current blistering pace.
Operating Margins Stabilizing as Reinvestment Continues
Despite a healthy Gross Margin profile (38.4% for FY25, up from 37.6%), adjusted operating margin remained stubbornly stable in Q4 at 18.8% (flat YoY). This reflects the structural reality that EXL must heavily reinvest its gross profits into specialized talent, R&D, and new LLM development to maintain its technological edge.
Macroeconomic Caution Persists
While EXL argues its services are counter-cyclical (helping clients cut costs in tough times), the broader macroeconomic environment continues to influence client decision-making cycles. The conservative 2026 guidance likely bakes in elongated sales cycles and careful enterprise IT budget scrutiny.
Other KPIs
Accelerating/Improving. Up 80 basis points from 37.6% in 2024. This proves that the mix-shift toward higher-value Data & AI services is structurally improving the profitability of the revenue base, even if SG&A reinvestments obscure it at the operating line.
The Board authorized a new $500M buyback program effective February 2026 for a two-year period. This represents roughly 7-8% of the company's market cap and signals high confidence in future free cash flow generation, providing a strong floor for the stock amid decelerating top-line guidance.
G&A surged 19.8% YoY in Q4, significantly outpacing the 12.7% revenue growth. This line item explains why operating margins aren't expanding as fast as gross margins—the company is paying a premium for AI-native talent and bearing the costs of its Q1 2025 organizational restructuring.
Guidance
Decelerating. The midpoint implies 10.0% YoY growth, a step down from the 13.6% growth achieved in 2025. This indicates a normalization of demand or tougher comparisons, breaking the recent trend of mid-teens expansion.
Decelerating. The midpoint of $2.165 implies 11.0% YoY growth, down from the 18.0% growth delivered in 2025. This suggests that the massive operating leverage seen in the first half of 2025 is largely in the rearview mirror.
Key Questions
Insurance Segment Weakness
Insurance revenue growth decelerated to 7.2% in Q4. Is this a function of macro-driven budget delays, increased competitive intensity, or a structural limit to AI adoption pacing in this specific vertical?
Decoupling of AI Hype and Revenue Growth
If EXLdata.ai and proprietary LLMs are successfully expanding wallet share and total addressable market as stated, why does 2026 guidance forecast a 300+ basis point deceleration in top-line growth?
Margin Expansion Ceiling
With gross margins now exceeding 38%, how much of that benefit will be allowed to drop to the operating income line in 2026 versus being continuously recycled into AI R&D and specialized talent?